OSE Immuno: appointment of Alexandre Lebeaut as independent director

(Boursier.com) — OSE Immuno announces the appointment of Alexandre Lebeaut by cooptation as independent director of the company. Alexandre Lebeaut has more than 25 years of rich experience and leadership in innovation, research and development, ranging from preclinical to market, with major successes, particularly in the fields of immunology, oncology, immuno-inflammation and infectious diseases. He has held various international positions, mainly in the United States and in particular within Bluebird Bio, Sanofi, Novartis and Schering Plow Research Institute. More recently, Alexandre Lebeaut was “Executive Vice-President R&D and Chief Scientific Officer” at Ipsen in the United States. He currently leads an American non-profit organization, I-ACT for Children (Institute for Advanced Clinical Trials for Children), based in Maryland and dedicated to the development of pediatric drugs.

Of French and American nationality, Alexandre Lebeaut is a Doctor of Medicine (University of Paris Diderot Paris VII) and a pediatrician (University of Paris Descartes).

“We are delighted to welcome Alexandre, whose successful American and international experience is very rich, in strategic Research and Development functions, particularly in immunology. His widely recognized expertise fits perfectly into our new phase of growth focused on the preclinical and clinical advancement of a diversified portfolio of first-in-class products in immuno-oncology and immunology & inflammation”, comments Dominique Costantini, President and CEO of OSE Immunotherapeutics.

“I am very honored to join the Board of Directors of OSE, which I thank for its confidence. Alongside the management team, I will be happy to contribute to the growth of the Company at a critical moment in its evolution in positioning OSE as a recognized leader in immunotherapy and developing its international visibility”, adds Alexandre Lebeaut.

On the proposal of the Remuneration and Appointments Committee, the Board unanimously decided to co-opt Alexandre Lebeaut as an independent member of the Board. This appointment will be subject to ratification at the next annual general meeting.